{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:44:59Z","timestamp":1793407499247,"version":"4.5.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004896","name":"Eisai Incorporated","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004896","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s40120-023-00492-7","type":"journal-article","created":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T18:02:28Z","timestamp":1684173748000},"page":"1133-1157","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Predicting the Societal Value of Lecanemab in Early Alzheimer\u2019s Disease in Japan: A Patient-Level Simulation"],"prefix":"10.1007","volume":"12","author":[{"given":"Ataru","family":"Igarashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mie Kasai","family":"Azuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanwu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weicheng","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Sardesai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri","family":"Folse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameya","family":"Chavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoyuki","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4003-3192","authenticated-orcid":false,"given":"Amir Abbas","family":"Tahami Monfared","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,15]]},"reference":[{"issue":"1","key":"492_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12929-019-0609-7","volume":"27","author":"L-K Huang","year":"2020","unstructured":"Huang L-K, Chao S-P, Hu C-J. Clinical trials of new drugs for Alzheimer disease. J Biomed Sci. 2020;27(1):1\u201313.","journal-title":"J Biomed Sci"},{"key":"492_CR2","unstructured":"Asada T. Prevalence of dementia and response to life dysfunction due to dementia in urban areas, Health Labour Sciences Research Grants, Dementia Countermeasures Comprehensive Research Project 2011-2012 Research Report. 2013."},{"key":"492_CR3","unstructured":"Prince MJ, Wimo A, Guerchet MM, Ali GC, Wu Y-T, Prina M. World Alzheimer Report 2015\u2014the global impact of dementia: an analysis of prevalence, incidence, cost and trends. Alzheimer's Disease International, 2015. 84 p. https:\/\/www.alzint.org\/u\/WorldAlzheimerReport2015.pdf. Accessed 15 Mar 2023."},{"key":"492_CR4","unstructured":"World Health Organization. Dementia 2023. https:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/dementia. Accessed 20 Feb 2023."},{"issue":"2","key":"492_CR5","doi-asserted-by":"publisher","first-page":"807","DOI":"10.3233\/JAD-201508","volume":"84","author":"H Fukuda","year":"2021","unstructured":"Fukuda H, Ono R, Maeda M, Murata F. Medical care and long-term care expenditures attributable to Alzheimer\u2019s disease onset: results from the LIFE Study. J Alzheimers Dis. 2021;84(2):807\u201317.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"492_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12877-021-02540-z","volume":"21","author":"N Nakahori","year":"2021","unstructured":"Nakahori N, Sekine M, Yamada M, Tatsuse T, Kido H, Suzuki M. Future projections of the prevalence of dementia in Japan: results from the Toyama Dementia Survey. BMC Geriatr. 2021;21(1):1\u201310.","journal-title":"BMC Geriatr"},{"key":"492_CR7","doi-asserted-by":"publisher","unstructured":"2022 Alzheimer's disease facts and figures. Alzheimers Dement. 2022;18(4):700\u201389. https:\/\/doi.org\/10.1002\/alz.12638.","DOI":"10.1002\/alz.12638"},{"issue":"10","key":"492_CR8","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1111\/ggi.13764","volume":"19","author":"H Takechi","year":"2019","unstructured":"Takechi H, Kokuryu A, Kuzuya A, Matsunaga S. Increase in direct social care costs of Alzheimer\u2019s disease in Japan depending on dementia severity. Geriatr Gerontol Int. 2019;19(10):1023\u20139.","journal-title":"Geriatr Gerontol Int"},{"key":"492_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/alz.055092","volume":"17","author":"K Shibata","year":"2021","unstructured":"Shibata K, Ariyoshi K, Azuma M, Shiromi K, Hioki S, Ishii M. Challenges of defining healthcare costs for people with mild cognitive impairment (MCI) based on the claim database analysis in Japan. Alzheimers Dement. 2021;17:e055092.","journal-title":"Alzheimers Dement"},{"key":"492_CR10","doi-asserted-by":"crossref","unstructured":"Ikeda S, Mimura M, Ikeda M, Wada-Isoe K, Azuma M, Inoue S, et al. Economic burden of Alzheimer\u2019s disease dementia in Japan. Journal of Alzheimer's Disease. 2021;81(1):309\u201319.","DOI":"10.3233\/JAD-210075"},{"issue":"6","key":"492_CR11","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1136\/jnnp.70.6.711","volume":"70","author":"GB Frisoni","year":"2001","unstructured":"Frisoni GB. Structural imaging in the clinical diagnosis of Alzheimer\u2019s disease: problems and tools. J Neurol Neurosurg Psychiatry. 2001;70(6):711\u20138. https:\/\/doi.org\/10.1136\/jnnp.70.6.711.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"492_CR12","doi-asserted-by":"publisher","first-page":"109","DOI":"10.14283\/jpad.2017.12","volume":"4","author":"J Cummings","year":"2017","unstructured":"Cummings J, Fox N. Defining disease modifying therapy for Alzheimer\u2019s disease. J Prev Alzheimers Dis. 2017;4(2):109\u201315. https:\/\/doi.org\/10.14283\/jpad.2017.12.","journal-title":"J Prev Alzheimers Dis"},{"issue":"2","key":"492_CR13","first-page":"109","volume":"4","author":"J Cummings","year":"2017","unstructured":"Cummings J, Fox N. Defining disease modifying therapy for Alzheimer\u2019s disease. J Prev Alzheimers Dis. 2017;4(2):109.","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"492_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388(1):9\u201321.","journal-title":"N Engl J Med"},{"issue":"2","key":"492_CR15","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s40120-022-00350-y","volume":"11","author":"AA Tahami Monfared","year":"2022","unstructured":"Tahami Monfared AA, Tafazzoli A, Ye W, Chavan A, Zhang Q. Long-term health outcomes of lecanemab in patients with early Alzheimer\u2019s disease using simulation modeling. Neurol Ther. 2022;11(2):863\u201380.","journal-title":"Neurol Ther"},{"issue":"3","key":"492_CR16","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s40120-022-00373-5","volume":"11","author":"AA Tahami Monfared","year":"2022","unstructured":"Tahami Monfared AA, Tafazzoli A, Chavan A, Ye W, Zhang Q. The potential economic value of lecanemab in patients with early Alzheimer\u2019s disease using simulation modeling. Neurol Ther. 2022;11(3):1285\u2013307.","journal-title":"Neurol Ther"},{"issue":"1","key":"492_CR17","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jval.2019.10.005","volume":"23","author":"M Hasegawa","year":"2020","unstructured":"Hasegawa M, Komoto S, Shiroiwa T, Fukuda T. Formal implementation of cost-effectiveness evaluations in Japan: a unique health technology assessment system. Value Health. 2020;23(1):43\u201351. https:\/\/doi.org\/10.1016\/j.jval.2019.10.005.","journal-title":"Value Health"},{"key":"492_CR18","doi-asserted-by":"publisher","first-page":"102346","DOI":"10.1016\/j.jhealeco.2020.102346","volume":"72","author":"DN Lakdawalla","year":"2020","unstructured":"Lakdawalla DN, Phelps CE. Health technology assessment with risk aversion in health. J Health Econ. 2020;72:102346. https:\/\/doi.org\/10.1016\/j.jhealeco.2020.102346.","journal-title":"J Health Econ"},{"key":"492_CR19","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.trci.2018.01.001","volume":"4","author":"AR Kansal","year":"2018","unstructured":"Kansal AR, Tafazzoli A, Ishak KJ, Krotneva S, ADNI Collaboration. Alzheimer\u2019s disease Archimedes condition-event simulator: development and validation. Alzheimers Dement (N Y). 2018;4:76\u201388.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"5","key":"492_CR20","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1177\/0272989X12454577","volume":"32","author":"JJ Caro","year":"2012","unstructured":"Caro JJ, Briggs AH, Siebert U, Kuntz KM. Modeling good research practices\u2014overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force\u20141. Med Decis Mak. 2012;32(5):667\u201377.","journal-title":"Med Decis Mak"},{"issue":"4","key":"492_CR21","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1007\/s40120-022-00393-1","volume":"11","author":"AA Tahami Monfared","year":"2022","unstructured":"Tahami Monfared AA, Tafazzoli A, Ye W, Chavan A, Deger KA, Zhang Q. A simulation model to evaluate the potential impact of disease-modifying treatments on burden of illness in Alzheimer\u2019s disease. Neurol Ther. 2022;11(4):1609\u201323.","journal-title":"Neurol Ther"},{"key":"492_CR22","unstructured":"Tafazzoli A, Weng J, Sutton K. Validating simulated cognition trajectories based on ADNI against trajectories from the National Alzheimer\u2019s Coordinating Center (NACC) dataset. 11th Clinical Trial on Alzheimer\u2019s Disease (CTAD). 2018."},{"key":"492_CR23","unstructured":"Alzheimer's Disease Neuroimaging Initiative. 2017. https:\/\/adni.loni.usc.edu\/. Accessed June 2021."},{"issue":"5","key":"492_CR24","doi-asserted-by":"publisher","first-page":"411","DOI":"10.2165\/11531870-000000000-00000","volume":"28","author":"D Getsios","year":"2010","unstructured":"Getsios D, Blume S, Ishak KJ, Maclaine GD. Cost effectiveness of donepezil in the treatment of mild to moderate Alzheimer\u2019s disease. Pharmacoeconomics. 2010;28(5):411\u201327.","journal-title":"Pharmacoeconomics"},{"issue":"11","key":"492_CR25","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1007\/s40273-014-0203-5","volume":"32","author":"S Guo","year":"2014","unstructured":"Guo S, Getsios D, Revankar N, et al. Evaluating disease-modifying agents: a simulation framework for Alzheimer\u2019s disease. Pharmacoeconomics. 2014;32(11):1129\u201339.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"492_CR26","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1046\/j.1532-5415.2002.50065.x","volume":"50","author":"GW Small","year":"2002","unstructured":"Small GW, McDonnell DD, Brooks RL, Papadopoulos G. The impact of symptom severity on the cost of Alzheimer\u2019s disease. J Am Geriatr Soc. 2002;50(2):321\u20137.","journal-title":"J Am Geriatr Soc"},{"key":"492_CR27","unstructured":"Council. TCSIM, Center for Outcomes Research and Economic Evaluation for Health, National Institute of Public Health (C2H). Guideline for preparing cost-effectiveness evaluation to the Central Social Insurance Medical Council Ver 3.0. 2022. https:\/\/c2h.niph.go.jp\/tools\/guideline\/guideline_en.pdf. Accessed Mar 2023."},{"issue":"1","key":"492_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-021-00813-8","volume":"13","author":"CJ Swanson","year":"2021","unstructured":"Swanson CJ, Zhang Y, Dhadda S, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody. Alzheimer\u2019s Res Ther. 2021;13(1):1\u201314.","journal-title":"Alzheimer's Res Ther"},{"issue":"8","key":"492_CR29","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1001\/archneur.65.8.1091","volume":"65","author":"SE O\u2019Bryant","year":"2008","unstructured":"O\u2019Bryant SE, Waring SC, Cullum CM, et al. Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer\u2019s Research Consortium study. Arch Neurol. 2008;65(8):1091\u20135.","journal-title":"Arch Neurol"},{"key":"492_CR30","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.2147\/CIA.S64107","volume":"9","author":"Y Takata","year":"2014","unstructured":"Takata Y, Ansai T, Soh I, et al. Cognitive function and 10 year mortality in an 85 year-old community-dwelling population. Clin Interv Aging. 2014;9:1691\u20139. https:\/\/doi.org\/10.2147\/CIA.S64107.","journal-title":"Clin Interv Aging"},{"issue":"3","key":"492_CR31","doi-asserted-by":"publisher","first-page":"891","DOI":"10.3233\/JAD-191055","volume":"75","author":"A Wimo","year":"2020","unstructured":"Wimo A, Handels R, Winblad B, et al. Quantifying and describing the natural history and costs of Alzheimer\u2019s disease and effects of hypothetical interventions. J Alzheimers Dis. 2020;75(3):891\u2013902.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"492_CR32","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1159\/000265553","volume":"29","author":"K Andersen","year":"2010","unstructured":"Andersen K, Lolk A, Martinussen T, Kragh-S\u00f8rensen P. Very mild to severe dementia and mortality: a 14-year follow-up\u2013the Odense study. Dement Geriatr Cogn Disord. 2010;29(1):61\u20137.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"492_CR33","unstructured":"Ministry of Health Labour and Welfare. Statistics of long-term care benefit expenditures (cases assessed in April 2018). https:\/\/www.mhlw.go.jp\/toukei\/saikin\/hw\/kaigo\/kyufu\/2018\/04.html. Accessed Mar 15."},{"issue":"8","key":"492_CR34","doi-asserted-by":"publisher","first-page":"777","DOI":"10.2174\/1567205015666180119092427","volume":"15","author":"M Davis","year":"2018","unstructured":"Davis M, O\u2019Connell T, Johnson S, et al. Estimating Alzheimer\u2019s disease progression rates from normal cognition through mild cognitive impairment and stages of dementia. Curr Alzheimer Res. 2018;15(8):777\u201388.","journal-title":"Curr Alzheimer Res"},{"key":"492_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2021.101339","volume":"68","author":"KI Avgerinos","year":"2021","unstructured":"Avgerinos KI, Ferrucci L, Kapogiannis D. Effects of monoclonal antibodies against amyloid-\u03b2 on clinical and biomarker outcomes and adverse event risks: a systematic review and meta-analysis of phase\u00a0III RCTs in Alzheimer\u2019s disease. Ageing Res Rev. 2021;68: 101339.","journal-title":"Ageing Res Rev"},{"key":"492_CR36","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.dadm.2018.04.001","volume":"10","author":"E Fletcher","year":"2018","unstructured":"Fletcher E, Filshtein TJ, Harvey D, et al. Staging of amyloid \u03b2, t-tau, regional atrophy rates, and cognitive change in a nondemented cohort: results of serial mediation analyses. Alzheimers Dement (Amst). 2018;10:382\u201393.","journal-title":"Alzheimers Dement (Amst)"},{"issue":"1","key":"492_CR37","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s13195-022-01124-2","volume":"14","author":"E McDade","year":"2022","unstructured":"McDade E, Cummings JL, Dhadda S, et al. Lecanemab in patients with early Alzheimer\u2019s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study. Alzheimers Res Ther. 2022;14(1):191.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"492_CR38","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s13195-022-01129-x","volume":"14","author":"S Dhadda","year":"2022","unstructured":"Dhadda S, Kanekiyo M, Li D, et al. Consistency of efficacy results across various clinical measures and statistical methods in the lecanemab phase 2 trial of early Alzheimer\u2019s disease. Alzheimers Res Ther. 2022;14(1):182. https:\/\/doi.org\/10.1186\/s13195-022-01129-x.","journal-title":"Alzheimers Res Ther"},{"key":"492_CR39","first-page":"1361","volume":"25","author":"S Kitamura","year":"2014","unstructured":"Kitamura S, Inoue S, Matsui D, Matsushita Y. Cost-effectiveness analysis for memantine monotherapy in patients with moderate and severe Alzheimer\u2019s disease. Jpn J Geriatr Psychiatry. 2014;25:1361\u201373.","journal-title":"Jpn J Geriatr Psychiatry"},{"issue":"11","key":"492_CR40","doi-asserted-by":"publisher","first-page":"e0206508","DOI":"10.1371\/journal.pone.0206508","volume":"13","author":"M Sado","year":"2018","unstructured":"Sado M, Ninomiya A, Shikimoto R, et al. The estimated cost of dementia in Japan, the most aged society in the world. PLoS ONE. 2018;13(11):e0206508. https:\/\/doi.org\/10.1371\/journal.pone.0206508.","journal-title":"PLoS ONE"},{"key":"492_CR41","unstructured":"Ministry of Health, Labour and Welfare (MHLW). National Health Insurance (NHI) Medical fee. 2022. Medical Service Fees. https:\/\/shirobon.net\/medicalfee\/latest\/ika\/r04_ika\/, in Japanese. Accessed 15 Mar 2023."},{"key":"492_CR42","unstructured":"Medical Data Vision. Company website. Analysis conducted by Eisai using MDV analyzer 2019 dataset 2020. https:\/\/en.mdv.co.jp\/service\/web-tools\/. Accessed July 28."},{"key":"492_CR43","unstructured":"Social Insurance Union of Societies Related to Internal Medicine. Proposal for the revision of National Health Insurance (NHI) reimbursement for 2022. https:\/\/fa.kyorin.co.jp\/naihoren\/shinryohoshu2022\/suggestion2022_p322.pdf, in Japanese, Accessed 15 Mar 2023."},{"issue":"1","key":"492_CR44","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3233\/JAD-201514","volume":"81","author":"T Ashizawa","year":"2021","unstructured":"Ashizawa T, Igarashi A, Sakata Y, et al. Impact of the severity of Alzheimer\u2019s disease on the quality of life, activities of daily living, and caregiving costs for institutionalized patients on anti-Alzheimer medications in Japan. J Alzheimers Dis. 2021;81(1):367\u201374. https:\/\/doi.org\/10.3233\/JAD-201514.","journal-title":"J Alzheimers Dis"},{"key":"492_CR45","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/00005650-199901000-00005","volume":"37","author":"PJ Neumann","year":"1999","unstructured":"Neumann PJ, Kuntz KM, Leon J, et al. Health utilities in Alzheimer\u2019s disease: a cross-sectional study of patients and caregivers. Med Care. 1999;37:27\u201332.","journal-title":"Med Care"},{"issue":"1","key":"492_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-020-00723-1","volume":"12","author":"F Landeiro","year":"2020","unstructured":"Landeiro F, Mughal S, Walsh K, et al. Health-related quality of life in people with predementia Alzheimer\u2019s disease, mild cognitive impairment or dementia measured with preference-based instruments: a systematic literature review. Alzheimers Res Ther. 2020;12(1):1\u201314.","journal-title":"Alzheimers Res Ther"},{"issue":"11","key":"492_CR47","doi-asserted-by":"publisher","first-page":"e038987","DOI":"10.1136\/bmjopen-2020-038987","volume":"10","author":"H Igarashi","year":"2020","unstructured":"Igarashi H, Ueda K, Jung S, Cai Z, Chen Y, Nakamura T. Social burden of people with the migraine diagnosis in Japan: evidence from a population-based cross-sectional survey. BMJ Open. 2020;10(11):e038987. https:\/\/doi.org\/10.1136\/bmjopen-2020-038987.","journal-title":"BMJ Open"},{"issue":"4","key":"492_CR48","doi-asserted-by":"publisher","first-page":"358","DOI":"10.2174\/156720510791162430","volume":"7","author":"J Mesterton","year":"2010","unstructured":"Mesterton J, Wimo A, Langworth S, Winblad B, Jonsson L. Cross sectional observational study on the societal costs of Alzheimer\u2019s disease. Curr Alzheimer Res. 2010;7(4):358\u201367.","journal-title":"Curr Alzheimer Res"},{"issue":"6","key":"492_CR49","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1212\/WNL.52.6.1138","volume":"52","author":"PJ Neumann","year":"1999","unstructured":"Neumann PJ, Hermann R, Kuntz K, et al. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer\u2019s disease. Neurology. 1999;52(6):1138\u201345.","journal-title":"Neurology"},{"issue":"8","key":"492_CR50","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1080\/03007995.2021.1922369","volume":"37","author":"M Nakanishi","year":"2021","unstructured":"Nakanishi M, Igarashi A, Ueda K, et al. Costs and resource use of community-dwelling patients with Alzheimer\u2019s disease in Japan: 18-month results from the GERAS-J study. Curr Med Res Opin. 2021;37(8):1331\u20139. https:\/\/doi.org\/10.1080\/03007995.2021.1922369.","journal-title":"Curr Med Res Opin"},{"key":"492_CR51","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12959","author":"RC Petersen","year":"2023","unstructured":"Petersen RC, Aisen PS, Andrews JS, et al. Expectations and clinical meaningfulness of randomized controlled trials. Alzheimers Dement. 2023. https:\/\/doi.org\/10.1002\/alz.12959.","journal-title":"Alzheimers Dement"},{"issue":"6","key":"492_CR52","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1002\/hec.1741","volume":"21","author":"N Hawkins","year":"2012","unstructured":"Hawkins N, Richardson G, Sutton AJ, et al. Surrogates, meta-analysis and cost-effectiveness modelling: a combined analytic approach. Health Econ. 2012;21(6):742\u201356. https:\/\/doi.org\/10.1002\/hec.1741.","journal-title":"Health Econ"},{"issue":"4","key":"492_CR53","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1002\/alz.12422","volume":"18","author":"DP Veitch","year":"2022","unstructured":"Veitch DP, Weiner MW, Aisen PS, et al. Using the Alzheimer\u2019s Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer\u2019s disease. Alzheimers Dement. 2022;18(4):824\u201357. https:\/\/doi.org\/10.1002\/alz.12422.","journal-title":"Alzheimers Dement"},{"key":"492_CR54","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/j.jalz.2018.03.009","volume":"14","author":"T Iwatsubo","year":"2018","unstructured":"Iwatsubo T, Iwata A, Suzuki K, et al. Japanese and North American Alzheimer\u2019s Disease Neuroimaging Initiative studies: harmonization for international trials. Alzheimers Dement. 2018;14:1077\u201387.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"492_CR55","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.trci.2019.06.004","volume":"5","author":"T Yagi","year":"2019","unstructured":"Yagi T, Kanekiyo M, Ito J, et al. Identification of prognostic factors to predict cognitive decline of patients with early Alzheimer\u2019s disease in the Japanese Alzheimer\u2019s Disease Neuroimaging Initiative study. Alzheimers Dement (N Y). 2019;5(1):364\u201373.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"8","key":"492_CR56","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1080\/14737167.2022.2118113","volume":"22","author":"A Igarashi","year":"2022","unstructured":"Igarashi A, Ikeda S. Value assessment of new interventions for Alzheimer\u2019s disease dementia in Japan based on literature review and group interview. Expert Rev Pharmacoecon Outcomes Res. 2022;22(8):1163\u201370. https:\/\/doi.org\/10.1080\/14737167.2022.2118113.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"492_CR57","unstructured":"Ministry of Health, Labour, and Welfare. What's new 2018. https:\/\/www.mhlw.go.jp\/english\/new-info\/2018.html. Accessed 15 Mar 2023."}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-023-00492-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-023-00492-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-023-00492-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T17:08:59Z","timestamp":1700154539000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-023-00492-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,15]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["492"],"URL":"https:\/\/doi.org\/10.1007\/s40120-023-00492-7","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,15]]},"assertion":[{"value":"25 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}